Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

DCTH
Delcath Systems Inc
stock NASDAQ

Market Open
Aug 6, 2026 11:02:51 AM EDT
15.43USD+22.266%(+2.81)1,333,111
15.41Bid   15.44Ask   0.03Spread
Pre-market
Aug 6, 2026 9:29:30 AM EDT
14.25USD+12.916%(+1.63)17,104
After-hours
Aug 4, 2026 4:00:30 PM EDT
13.14USD-0.152%(-0.02)0
OverviewOption ChainMax PainOptionsPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 25, 2022
04:01PM EST  Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced thatDavid Hoffman has been appointed as General Counsel and Corporate Secretary. Mr. Hoffman will also serve as Delcaths Chief Compliance Officer.   GlobeNewswire Inc
Jan 7, 2022
09:00AM EST  Delcath Systems, Inc. (Nasdaq:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will participate in an upcoming virtual investor conference:   GlobeNewswire Inc
Dec 10, 2021
12:41PM EST  Benzinga's Top Ratings Upgrades, Downgrades For December 10, 2021   Benzinga
07:21AM EST  HC Wainwright & Co. Initiates Coverage On Delcath Systems with Buy Rating, Announces Price Target of $25   Benzinga
Dec 2, 2021
08:10AM EST  UPDATE: Delcath Says 'While overall survival data continues to mature, a Hazard Ratio (HR) analysis of survival at 12-months yielded a statistically significant advantage for HEPZATO over a Best Alternative Care'   Benzinga
08:09AM EST  UPDATE: Delcath Reports Primary Overall Response Endpoint Exceeded The Predefined Threshold For Success With Median Duration Of Response Of 14 Months   Benzinga
08:07AM EST  Delcath Shares To Resume Trade At 8:30 a.m. EST   Benzinga
08:02AM EST  Delcath Systems, Inc. Announces Phase 3 FOCUS Trial Results For Hepzato In Liver-Dominant Metastatic Ocular Melanoma, Including Initial Survival Data Analysis   Benzinga
08:00AM EST  On final analysis of the primary overall response (ORR) endpoint, HEPZATO further exceeded the predefined threshold for success with a median duration of response of 14 months   GlobeNewswire Inc
07:51AM EST  The Daily Biotech Pulse: Moderna, Pfizer-BioNTech Ink New Vaccine Deals With UK, GSK-Vir Antibody Show Activity Against Omicron, Chemomab Gets Clearance   Benzinga
Nov 30, 2021
08:30AM EST  Delcath Systems, Inc. (Nasdaq:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today its agenda and distinguished speaker list for a comprehensive Investor Update Meeting taking place Thursday, December 2nd, from 10:00am ET 1:30pm EST.   GlobeNewswire Inc
Nov 9, 2021
11:42AM EST  Recap: Delcath Systems Q3 Earnings   Benzinga
11:36AM EST  Delcath Systems Q3 EPS $(0.94) Beats $(1.08) Estimate, Sales $522.00K Beat $490.00K Estimate   Benzinga
11:25AM EST  Earnings Scheduled For November 9, 2021   Benzinga
07:30AM EST  Delcath Systems, Inc. (Nasdaq:DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today reported business highlights and financial results for the third quarter ended September 30, 2021.   GlobeNewswire Inc
Nov 8, 2021
09:00AM EST  Delcath Systems, Inc. (Nasdaq:DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today it will participate in an upcoming virtual investor conference:   GlobeNewswire Inc
Nov 5, 2021
09:00AM EDT  Delcath Systems, Inc. (Nasdaq:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a comprehensive Investor Update event on Thursday, December 2nd, from 10:00am ET 1:00pm ET.   GlobeNewswire Inc
Oct 25, 2021
04:01PM EDT  Delcath Systems, Inc. (Nasdaq:DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today it will host a conference call on Nov 9, 2021 at 8:30 AM Eastern Time to discuss results for its third quarter ended September 30, 2021.   GlobeNewswire Inc
Sep 2, 2021
09:00AM EDT  Delcath Systems, Inc. (Nasdaq:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will participate in three upcoming conferences:   GlobeNewswire Inc
Aug 26, 2021
09:30AM EDT  Clinicaltrials.gov Site Shows Delcath Systems Study 'An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma' Available   Benzinga
Aug 10, 2021
07:54AM EDT  Delcath Systems: Q2 Earnings Insights   Benzinga
07:30AM EDT  Delcath Systems, Inc. (Nasdaq:DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today reported business highlights and financial results for the second quarter ended June 30, 2021.   GlobeNewswire Inc
04:05AM EDT  Earnings Scheduled For August 10, 2021   Benzinga
Aug 9, 2021
11:35AM EDT  Earnings Preview For Delcath Systems   Benzinga
07:30AM EDT  Delcath Systems Secures Up to a $20.0 Million Debt Facility with   GlobeNewswire Inc
Jul 28, 2021
09:00AM EDT  Delcath Systems, Inc. (Nasdaq:DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today it will host a conference call on August 10, 2021 at 8:30 AM Eastern Time to discuss results for its second quarter ended June 30, 2021.   GlobeNewswire Inc
Jul 7, 2021
09:00AM EDT  Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today that the company will present at Access to Giving Virtual Conference. The presentation will be given by Delcaths Chief Executive Officer, Gerard Michel. The conference is free to all registrants.   GlobeNewswire Inc
Jun 30, 2021
09:57AM EDT  Delcath Form 4 Filing From Co. Director, Rosalind Advisors, Shows Purchase Of 500K Shares At Average Price OF $11.56/Share   Benzinga
Jun 25, 2021
04:46PM EDT  Delcath Systems Inc Files For Mixed Shelf Of Up To $100M   Benzinga
Jun 17, 2021
09:58AM EDT  Return On Capital Employed Overview: Delcath Systems   Benzinga
Jun 14, 2021
09:57AM EDT  5 Value Stocks To Watch In The Healthcare Sector   Benzinga
Jun 8, 2021
09:14AM EDT  Delcath Systems Set To Join Russell Microcap Index June 28   Benzinga
09:00AM EDT  Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, is set to join the Russell Microcap Index at the conclusion of the 2021 Russell indexes annual reconstitution effect after the US market opens on June 28, according to a preliminary list of additions posted June 4.   GlobeNewswire Inc
Jun 7, 2021
12:21PM EDT  Delcath Systems' Hepzato Achieves 44% Best Overall Response Compared to Best Alternative Care in Eye Cancer   Benzinga
07:36AM EDT  Delcath Systems Announces Results from Delcath Systems' FOCUS Trial Met The Primary Endpoint   Benzinga
07:30AM EDT  As Previously Disclosed, the Prespecified Primary Endpoint, Objective Response Rate, Has Been Met by Exceeding the 95% CI Lower Bound Threshold for Success   GlobeNewswire Inc
Jun 3, 2021
09:00AM EDT  Delcath Systems, Inc. (Nasdaq:DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today announced that management will present at:   GlobeNewswire Inc
Jun 2, 2021
09:53AM EDT  Looking Into Delcath Systems's Return On Capital Employed   Benzinga
May 26, 2021
09:00AM EDT  Delcath Systems, Inc. (Nasdaq:DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today that management will present at:   GlobeNewswire Inc
May 11, 2021
02:10PM EDT  Delcath Systems shares were trading lower after the company reported worse-than-expected Q1 EPS results.   Benzinga
12:47PM EDT  Earnings Scheduled For May 11, 2021   Benzinga
08:56AM EDT  Delcath Systems: Q1 Earnings Insights   Benzinga
08:25AM EDT  Delcath Systems Inc. (DCTH) reported that its first-quarter net loss was $6.8 million or $1.04 per share, compared to a net income of $7.9 million last year.   RTTNews
08:14AM EDT  Delcath Systems Q1 Net Loss $6.8 Mln Or $1.04/Shr   RTTNews
08:11AM EDT  Delcath Systems Q1 EPS $(1.04) Misses $(0.98) Estimate   Benzinga
08:00AM EDT  Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financial results for the first quarter ended March 31, 2021.   GlobeNewswire Inc
04:14AM EDT  Earnings Scheduled For May 11, 2021   Benzinga
Apr 30, 2021
04:01PM EDT  Delcath Systems, Inc. (Nasdaq:DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today it will host a conference call on May 11, 2021 at 8:30 AM Eastern Time to discuss results for its first quarter ended March 31, 2021.   GlobeNewswire Inc
09:02AM EDT  Delcath Systems Announces Oral Presentation At American Society Of Clinical Oncology Annual Meeting Jun. 4   Benzinga
09:00AM EDT  A Presentation of Positive Preliminary Efficacy Results from the FOCUS Phase III trial   GlobeNewswire Inc
Apr 21, 2021
08:43AM EDT  Delcath Systems Announces National Institute for Health and Care Excellence Has Updated Its Guidance For CHEMOSAT To Recommend CHEMOSAT Be Categorized Under Special Arrangement Designation   Benzinga
08:38AM EDT  Delcath Systems, Inc. Announces Revised NICE Guidance for CHEMOSAT   GlobeNewswire Inc
Apr 6, 2021
10:02AM EDT  Roth Capital Maintains Buy on Delcath Systems, Raises Price Target to $25   Benzinga
Apr 5, 2021
03:12PM EDT  Wrapping Up March With With A Steady Green Streak   Benzinga
Mar 31, 2021
02:55PM EDT  Delcath Systems, Inc. Shares Additional Information Regarding   GlobeNewswire Inc
02:31PM EDT  Mid-Afternoon Market Update: Crude Oil Down 1.5%; Greenlane Shares Spike Higher   Benzinga
10:17AM EDT  Mid-Morning Market Update: Markets Mostly Higher; Walgreens Reports Mixed Q2 Results   Benzinga
08:18AM EDT  Recap: Delcath Systems Q4 Earnings   Benzinga
08:06AM EDT  Delcath Stock Moves Higher After Hepzato Achieves ORR Of 29.2% Beating Prespecified Threshold In Eye Cancer Study   Benzinga
07:53AM EDT  Delcath Systems Reports Positive Preliminary Results From   RTTNews
07:46AM EDT  Delcath Systems Q4 PRoduct Revenue $379K, Down From $398K YoY   Benzinga
07:45AM EDT  Delcath Systems, Inc. Announces Fourth Quarter 2020 Results,   GlobeNewswire Inc
07:41AM EDT  The Daily Biotech Pulse: Pfizer Vaccine 100% Effective In Adolescents, Equillium Readout, Amgen Goes Shopping, Achilles IPO   Benzinga
07:37AM EDT  Delcath System Announces Prelim. Results From Phase 3 FOCUS Trial Of HEPZATO; Says 'Based on Preliminary Data, FOCUS Trial Achieves Prespecified Success Threshold'   Benzinga
07:37AM EDT  Delcath Announces Positive Top-line Preliminary Results From Phase 3 FOCUS Trial Of HEPZATO KIT   RTTNews
07:36AM EDT  Delcath Shares Halted Following Press Release Announcing Results From Phase 3 Trial Of Metastatic Ocular Melanoma Candidate   Benzinga
07:30AM EDT  Based on Preliminary Data, FOCUS Trial Achieves Prespecified Success Threshold   GlobeNewswire Inc
04:26AM EDT  Earnings Scheduled For March 31, 2021   Benzinga
Mar 27, 2021
01:01PM EDT  The Week Ahead In Biotech (March 28-April 3): Acadia's Dementia Drug Update, Clinical Readouts, Few Earnings In Holiday-Shortened Week   Benzinga
Mar 24, 2021
04:01PM EDT  Delcath Systems, Inc. (Nasdaq:DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today it will host a conference call on March 31, 2021 at 8:00 AM Eastern Time to discuss results for its fourth quarter ended December 31, 2020.   GlobeNewswire Inc
Mar 9, 2021
10:07AM EST  Benzinga's Top Ratings Upgrades, Downgrades For March 9, 2021   Benzinga
09:23AM EST  Canaccord Genuity Initiates Coverage On Delcath Systems with Buy Rating, Announces Price Target of $24   Benzinga
Mar 8, 2021
09:00AM EST  Delcath Systems, Inc. (Nasdaq:DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today that management will participate at these upcoming virtual investor conferences:   GlobeNewswire Inc
Feb 11, 2021
11:21AM EST  Stocks That Hit 52-Week Highs On Thursday   Benzinga
09:00AM EST  Delcath Systems, Inc. (Nasdaq:DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today that management will participate at these upcoming virtual investor conferences:   GlobeNewswire Inc
Jan 11, 2021
10:56AM EST  Delcath Systems, Inc. (Nasdaq:DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today that management will present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference.   GlobeNewswire Inc
Jan 5, 2021
10:11AM EST  Benzinga's Top Upgrades, Downgrades For January 5, 2021   Benzinga
06:19AM EST  BTIG Initiates Coverage On Delcath Systems with Buy Rating, Announces Price Target of $23   Benzinga
Dec 17, 2020
11:00AM EST  James Flynn Reports In 13G Filing An 8.75% Stake In Delcath Systems   Benzinga
Dec 14, 2020
02:03PM EST  Delcath Systems CEO Michel Buys 7,500 Shares @ Avg Price of $13.25/Share   Benzinga
Dec 11, 2020
10:31AM EST  Delcath Systems Announces Completion of Underwritten Public Offering   GlobeNewswire Inc
Dec 9, 2020
08:00AM EST  Delcath Systems Announces Pricing of Public Offering of Common Stock   GlobeNewswire Inc
08:00AM EST  Delcath Systems Prices 1.46M Shares At $13.25/Share   Benzinga
Dec 8, 2020
04:01PM EST  Delcath Systems Announces Proposed Public Offering of Common Stock   GlobeNewswire Inc
04:01PM EST  Delcath Reports Common Stock Offering, No Size Disclosed   Benzinga
Dec 7, 2020
07:30AM EST  Kevin Muir Joins Delcath Systems, Inc. as VP, Commercial Operations   GlobeNewswire Inc
Nov 11, 2020
08:18AM EST  Delcath Systems, Inc. (DCTH) reported a third quarter net loss of $5.0 million, compared to a net loss of $7.5 million, a year ago. Loss per share was $1.16 compared to a loss of $73.82.   RTTNews
08:10AM EST  Delcath System Q3 Net Loss $5.0 Mln Vs Net Loss $7.5 Mln Last Year   RTTNews
08:06AM EST  Delcath Systems Q3 EPS $(1.16) Beats $(1.63) Estimate, Sales $340.00K Miss $410.00K Estimate   Benzinga
08:00AM EST  Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financial results for the third quarter ended September 30, 2020.   GlobeNewswire Inc
04:09AM EST  Earnings Scheduled For November 11, 2020   Benzinga
Nov 2, 2020
04:01PM EST  Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of primary and metastatic cancers, today announced management will participate in the Oppenheimer Fall MedTech Summit on Thursday, November 12, 2020.   GlobeNewswire Inc
09:00AM EST  Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of primary and metastatic cancers, today announced that it will host a conference call on November 11, 2020 at 8:30 AM Eastern Time to discuss results for its third quarter ended September 30, 2020.   GlobeNewswire Inc
Oct 29, 2020
07:30AM EDT  Delcath Systems Announces a KOL Call on November 5, 2020 to   GlobeNewswire Inc
Oct 1, 2020
04:14PM EDT  Delcath Systems Appoints Gerard Michel As CEO   RTTNews
04:09PM EDT  Delcath Appoints Gerard Michel CEO   Benzinga
04:07PM EDT  -- Gerard Michel Brings the Experience Needed to Lead Delcath as it Transitions from a Development to Commercial Stage Company -- John Purpura Appointed Chief Operating Officer with Operational, Manufacturing and Regulatory Responsibilities   GlobeNewswire Inc
Sep 10, 2020
09:00AM EDT  Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of rare primary and metastatic cancers, today announced management will participate in two upcoming virtual investor conferences:   GlobeNewswire Inc
Aug 25, 2020
04:02PM EDT  Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of rare primary and metastatic cancers, today announced management will present at the LD Micro 500 Virtual Conference Tuesday, September 01, 2020 3:00 PM ET.   GlobeNewswire Inc
Aug 13, 2020
04:08PM EDT  Delcath Systems Q2 EPS $(1.90) Misses $(1.69) Estimate, Sales $379.00K Miss $440.00K Estimate   Benzinga
04:01PM EDT  Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announces financial results for the quarter ended June 30, 2020, and will host an earnings call on August 13, 2020 at 4:30 p.m.   GlobeNewswire Inc
04:03AM EDT  Earnings Scheduled For August 13, 2020   Benzinga
Aug 3, 2020
01:48PM EDT  Delcath to Present at Canaccord Genuity 40th Annual Growth Conference   GlobeNewswire Inc
Jul 20, 2020
05:11AM EDT  80 Biggest Movers From Friday   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC